Fut, nem toboroz3. fázis
MHB018A Treatment in Patients With Chronic Thyroid Eye Disease
A legfontosabb adatok
- Ki végzi
- Minghui Pharmaceutical (Hangzhou) Ltd
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Fázis
- 3. fázis
- Résztvevők
- 150 fő, tervezett
- Kezdés
- 2026. márc. 17.
- Várható befejezés
- 2028. aug. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- MHB018A injection
- MHB018A injection Placebo
- A regiszteradat frissítve
- 2026. szeptember 24.
Ki vehet részt
- Életkor
- 18 év – 75 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 32 feltétel megnézéseKevesebb
Ki vehet részt
- Subjects voluntarily participating in the study and signing the informed consent form
- Aged 18-75 years (inclusive), of any gender
- Clinical diagnosis of chronic Thyroid Eye Disease (TED) , with symptoms in the study eye more than 12 months and less than 10 years
- Subjects with a clinical diagnosis of moderate to severe TED at screening and baseline
- Does not require immediate surgical ophthalmological intervention, and no corrective surgery/orbital radiotherapy is planned during the study
- Diabetic subjects must have well-controlled stable disease
- Sufficient bone marrow and organ function
- Eligible subjects of childbearing potential (male and female) must agree to use reliable contraceptive methods; female subjects of childbearing potential must have a negative blood pregnancy test within 7 days before the first use of the study drug and must not be breastfeeding
- Subject is willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study; -
Ki nem vehet részt
- Subjects who have previously received orbital radiotherapy or ophthalmic surgery for TED
- Subjects who received oral or intravenous corticosteroids or corticosteroid eye drops/ointments for TED within 4 weeks before the first dose; subjects who received periorbital/orbital steroid injections within 3 months before the first dose
- Subjects who used oral or intravenous corticosteroids for reasons other than TED within 4 weeks prior to Screening, excluding local use (topical, nasal, inhalation)
- Any previous treatment with rituximab, tocilizumab, other immunosuppressive agent use within 3 months prior to Screening
- Previous treatment targeting IGF-1R
- Selenium and biotin must be discontinued 3 weeks prior to Screening and must not be restarted during the trial; however, taking a multivitamin that includes selenium and/or biotin is allowed
- Use of an investigational agent for any condition within 30 days prior to Screening or anticipated use during the course of the trial
- Acute cardiovascular disease history or treatment within 6 months before the first dose
- Drug or alcohol abuse during the screening period
- Subjects who received or planned to receive live or attenuated live vaccines within 4 weeks before the first dose or during the study period
- Subjects who underwent major surgery within 4 weeks before the first dose or are expected to undergo surgery during the study period or within 4 weeks after the study
- Known hypersensitivity to any of the components of MNB018A or prior hypersensitivity reactions to mAbs; -
- Identified pre-existing ophthalmic disease that, in the judgment of the Investigator, would preclude study participation or complicate interpretation of study results
- Malignant condition in the past 5 years before signing the ICF (except successfully treated basal/squamous cell carcinoma of the skin)
- Presence of poorly controlled hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg; Renal artery stenosis
- Hearing impairment history in either ear during the screening period; or abnormal pure tone audiometry results
- Biopsy-proven or clinically suspected inflammatory bowel disease
- Positive results for serum virology tests (defined as pos
- Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision within the last 6 months of two lines of Snellen chart, new visual field defect or color defect secondary to optic nerve involvement
- Corneal decompensation unresponsive to medical management
- Decrease in CAS of ≥ 2 points or decrease in proptosis of ≥ 2 mm between screening and baseline
- Free thyroxine (FT4) and free triiodothyronine (FT3) levels <50% above or below the normal reference range at screening
- Pregnant or lactating women
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered Q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from chronic TED.
A vizsgálat 2 csoportja
- MHB018A InjectionA vizsgált kezelés
subcutaneous injections of MHB018A injection, 450mg once every 4 weeks (q4w).
- MHB018A Injection PlaceboPlacebo, összehasonlításként
subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of MHB018A Injection in Subjects With Chronic Moderate-to-Severe Thyroid Eye Disease.
- A regiszteradat frissítve
- 2026. szeptember 24.